Medicinal cannabis

Australian Prescriber

Volumn 38, Issue 6, 2015, Pages 212-215

  Murnion, Bridin ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cannabidiol; Drug regulation; Medical marijuana; Nabiximols

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; NABILONE; NABIXIMOLS; RIMONABANT;

APPETITE DISORDER; ARTICLE; CANCER PAIN; CARDIOGENIC SHOCK; DRUG SURVEILLANCE PROGRAM; EPILEPSY; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTRAOCULAR PRESSURE; LAW; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; SPASTICITY; VISCERAL PAIN;

EID: 84949225742     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2015.072     Document Type: Article

References (31)

1. Skaper SD, Di Marzo V. Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philos Trans R Soc Lond B Biol Sci 2012;367:3193-200.
2. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012;367:3353-63.
3. Therapeutic Goods Administration. Reasons for the medicines scheduling delegates final decisions, March 2015 (Medicines). Advisory Committee on Medicines Scheduling meeting, 18 November 2014. Canberra: Australian Government Department of Health; 2015. www.tga.gov.au/book/part-final-decisions-matters-referred-expert-advisory-committee-2 [cited 2015 Nov 4]
4. Mather LE, Rauwendaal ER, Moxham-Hall VL, Wodak AD. (Re)introducing medicinal cannabis. Med J Aust 2013;199:759-61.
5. Brunt TM, van Genugten M, Höner-Snoeken K, van de Velde MJ, Niesink RJ. Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. J Clin Psychopharmacol 2014;34:344-9.
6. Office for Medicinal Cannabis. The Hague: Netherlands Ministry of Health, Welfare and Sport; 2015. www.cannabisbureau.nl/English [cited 2015 Nov 4]
7. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
8. Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013;75:323-33.
9. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev 2010;62:588-631.
10. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 2005;40:2-14.
11. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:1556-63.
12. Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 2013;4:CD005175.
13. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011;72:735-44.
14. Faculty of Pain Medicine. Statement on ‘Medicinal Cannabis’ with particular reference to its use in the management of patients with chronic non-cancer pain. Melbourne: Australian and New Zealand College of Anaesthetists; 2015.
15. National Cancer Institute. Cannabis and cannabinoids – for health professionals (PDQ). Bethesda (MD): National Institutes of Health; 2015. www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq [cited 2015 Nov 4]
16. Cancer Council Australia. Medical use of cannabis: a joint position statement with the Clinical Oncology Society of Australia. Sydney: Cancer Council Australia; 2014. http://wiki.cancer.org.au/policy/Position_statement_-_Medical_use_of_cannabis [cited 2015 Nov 4]
17. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802.
18. Devinsky O, Sullivan J, Friedman D, Thiele E, Marsh E, Laux L, et al. Abstract 3.303. Efficacy and safety of Epidiolex (cannabidiol) in children and young adults with treatment-resistant epilepsy: initial data from an expanded access program. Chicago (IL): American Epilepsy Society; 2014. www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868751 [cited 2015 Nov 4]
19. Smethurst A. Desperate parents turn to medical marijuana in last-ditch effort to improve their children’s lives. Melbourne: Herald Sun [online edition]; 2014 Jan 12. www.heraldsun.com.au/news/victoria/desperate-parents-turn-to-medical-marijuana-in-lastditch-effort-to-improve-their-childrens-lives/story-fni0fit3-1226799787147 [cited 2015 Nov 4]
20. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014;71:281-91.
21. Public Statement on Acomplia (rimonabant): withdrawal of the marketing authorisation in the European Union. London: European Medicines Agency; 2009 Jan 30.
22. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374:1383-91.
23. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 2014;174:1668-73.
24. Bulletin series 18: The use of cannabis for medical purposes. Sydney: National Cannabis Prevention and Information Centre; 2014 Sep. https://ncpic.org.au/professionals/publications/bulletins/the-use-of-cannabis-for-medical-purposes/ [cited 2015 Nov 4]
25. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J 2013;280:1918-43.
26. Canadian Medical Protection Association. Medical marijuana: New regulations, new College guidance for Canadian doctors. Ottawa: CMPA; 2015 July. https://www.cmpa-acpm.ca/en/legal-and-regulatory-proceedings/-/asset_publisher/a9unChEc2NP9/content/medical-marijuana-new-regulations-new-college-guidance-for-canadian-doctors [cited 2015 Nov 4]
27. Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician 2014;60:1083-90.
28. Pharmaceutical Health And Rational use of Medicines (PHARM) Committee. The National Strategy for Quality Use of Medicines. Canberra: Australian Government Department of Health; 2002.
29. Therapeutic Goods Administration. Legislation and legislative instruments. Canberra: Australian Government Department of Health; 2015. www.tga.gov.au/legislation-legislative-instruments [cited 2015 Nov 4]
30. Narcotic Drugs Act 1967, Comp. No. 9. (Jul 1, 2015).
31. Regulator of Medicinal Cannabis Bill 2014, Senate, Parl. No. 44. (Nov 27, 2014).